Diana D Cirstea

7PUBLICATIONS
40CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 27, 2026
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Viktoria Blumenberg, Filippo Birocchi, Angela Shih

|Jul 21, 2025
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.

Rahul Banerjee, Meera Mohan, Kai Rejeski

|Mar 31, 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.

Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham

|Mar 14, 2025
Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury.

E Bridget Kim, Jack E Malespini, Matthew Lei

|Feb 01, 2021
Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma.

Nathanael R Fillmore, Clark DuMontier, Cenk Yildirim

Pageof 2

Frequent Collaborators

5 joint publications

Andrew J Yee

4 joint publications

Andrew R Branagan

3 joint publications

Benjamin R Puliafito

3 joint publications

Marcela V Maus